Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CFO Alexis Desieno sold 25,118 shares of the business's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Alexis Desieno also recently made the following trade(s):
- On Wednesday, October 2nd, Alexis Desieno sold 7,487 shares of Cardlytics stock. The stock was sold at an average price of $3.08, for a total transaction of $23,059.96.
Cardlytics Price Performance
CDLX traded down $0.22 during trading on Friday, hitting $3.38. 1,038,456 shares of the company traded hands, compared to its average volume of 1,235,099. The stock's 50-day simple moving average is $3.73 and its two-hundred day simple moving average is $6.48. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.
Cardlytics (NASDAQ:CDLX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company's quarterly revenue was down 15.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.26) earnings per share. On average, sell-side analysts expect that Cardlytics, Inc. will post -1.72 EPS for the current fiscal year.
Institutional Trading of Cardlytics
A number of large investors have recently made changes to their positions in CDLX. Banco Santander S.A. purchased a new stake in Cardlytics in the 1st quarter valued at about $199,000. Vanguard Group Inc. increased its stake in shares of Cardlytics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company's stock valued at $32,046,000 after buying an additional 57,805 shares during the period. Quadrature Capital Ltd purchased a new stake in Cardlytics in the first quarter worth about $1,906,000. Price T Rowe Associates Inc. MD grew its holdings in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company's stock worth $432,000 after acquiring an additional 1,774 shares in the last quarter. Finally, Perbak Capital Partners LLP purchased a new position in Cardlytics during the 1st quarter valued at about $2,348,000. 68.10% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
CDLX has been the subject of several recent analyst reports. Northland Capmk cut shares of Cardlytics from a "strong-buy" rating to a "hold" rating in a report on Friday, August 16th. Lake Street Capital lowered shares of Cardlytics from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $18.00 to $5.00 in a report on Thursday, August 8th. Needham & Company LLC reiterated a "hold" rating on shares of Cardlytics in a research note on Thursday, November 7th. Northland Securities lowered Cardlytics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Finally, Craig Hallum raised Cardlytics from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $6.92.
Check Out Our Latest Stock Report on Cardlytics
About Cardlytics
(
Get Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
